DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+9.56%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$362M
AUM Growth
+$362M
(+2.7%)
Cap. Flow
-$9.38M
Cap. Flow
% of AUM
-2.59%
Top 10 Holdings %
Top 10 Hldgs %
55.78%
Holding
86
New
3
Increased
22
Reduced
21
Closed
10
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$2.11M |
| 2 |
Compass Therapeutics
CMPX
|
$1.37M |
| 3 |
Inogen
INGN
|
$1.04M |
| 4 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$975K |
| 5 |
Day One Biopharmaceuticals
DAWN
|
$961K |
Top Sells
| 1 |
Merus
MRUS
|
$3.31M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$3.05M |
| 3 |
TSVT
2seventy bio
TSVT
|
$2.12M |
| 4 |
UroGen Pharma
URGN
|
$1.96M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$1.93M |
Sector Composition
| 1 | Healthcare | 85.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
MediWound
MDWD
$179M
| $1.25M | 0.34% |
64,479
| – | – |
|
52
Structure Therapeutics
GPCR
$1.18B
| $1.22M | 0.34% |
59,000
| – | – |
|
53
Black Diamond Therapeutics
BDTX
$158M
| $1.17M | 0.32% |
471,000
+331,000
| +236% | +$821K |
|
54
Larimar Therapeutics
LRMR
$321M
| $1.07M | 0.3% |
371,434
| – | – |
|
55
VYNE Therapeutics
VYNE
$8.1M
| $1.05M | 0.29% |
636,103
| – | – |
|
56
Gossamer Bio
GOSS
$589M
| $1.05M | 0.29% |
849,921
-57,933
| -6% | -$71.3K |
|
|
PVLA
57
Palvella Therapeutics, Inc. Common Stock
PVLA
$579M
| $977K | 0.27% |
43,348
| – | – |
|
|
AUTL
58
Autolus Therapeutics
AUTL
$394M
| $970K | 0.27% |
425,616
-161,051
| -27% | -$367K |
|
59
Century Therapeutics
IPSC
$41.5M
| $952K | 0.26% |
1,704,232
| – | – |
|
60
Neurogene
NGNE
$276M
| $764K | 0.21% |
51,096
-404
| -0.8% | -$6.04K |
|
61
BioNTech
BNTX
$24.1B
| $745K | 0.21% |
7,000
-3,500
| -33% | -$373K |
|
62
PolyPid
PYPD
$54.7M
| $734K | 0.2% |
207,900
-83,373
| -29% | -$294K |
|
63
Korro Bio
KRRO
$226M
| $721K | 0.2% |
57,691
+10,605
| +23% | +$132K |
|
64
Compugen
CGEN
$134M
| $485K | 0.13% |
272,402
| – | – |
|
65
Aquestive Therapeutics
AQST
$471M
| $470K | 0.13% |
142,000
| – | – |
|
|
BCYC
66
Bicycle Therapeutics
BCYC
$500M
| $448K | 0.12% |
64,492
-16,307
| -20% | -$113K |
|
67
Erasca
ERAS
$391M
| $445K | 0.12% |
350,000
+10,000
| +3% | +$12.7K |
|
68
Adicet Bio
ACET
$60.2M
| $329K | 0.09% |
540,000
-60,000
| -10% | -$36.6K |
|
69
ADC Therapeutics
ADCT
$357M
| $327K | 0.09% |
122,081
-102,000
| -46% | -$273K |
|
70
Sutro Biopharma
STRO
$83.6M
| $312K | 0.09% |
437,079
| – | – |
|
71
Nektar Therapeutics
NKTR
$536M
| $258K | 0.07% |
+10,000
| New | +$258K |
|
72
Aprea Therapeutics
APRE
$9.09M
| $232K | 0.06% |
137,174
| – | – |
|
73
BiomX
PHGE
$14.3M
| $181K | 0.05% |
401,136
| – | – |
|
74
Procept Biorobotics
PRCT
$2.14B
| $173K | 0.05% |
+3,000
| New | +$173K |
|
75
InflaRx
IFRX
$122M
| $158K | 0.04% |
200,000
-250,000
| -56% | -$198K |
|